BD Cor system features MX instrument for infectious diseases

By staff writers

December 17, 2021 -- Becton Dickinson (BD) recently expanded its BD Cor system to include a new MX instrument for molecular testing of infectious diseases.

The new instrument and its first test for sexually transmitted infections have received the CE Mark for IVD directive 98/79/EC.

The first test available on the MX instrument is the BD CTGCTV2, which aims to use a single test to detect Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis.

The system assay was also included on the Australian Register for Therapeutic Goods following review by Australia's Medical Devices Regulator, the Therapeutic Goods Administration.

The BD Cor system.
BD has expanded its BD Cor system to include a new MX instrument for high-throughput molecular testing for infectious diseases. Image courtesy of BD.
The next phase of diagnostic testing is here and ready to scale
The new COVID-19 landscape combined with the arduous shifts in healthcare staffing further supports the integration of automation in diagnostics. While...
Qiagen and BD settle PCR patent lawsuit
Qiagen and Becton Dickinson (BD) have reached a settlement in a patent infringement lawsuit involving polymerase chain reaction (PCR) tests that Qiagen...
BD secures BARDA funds for development of COVID-19 test
Becton Dickinson (BD) has secured $24.7 million in funding from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop...
BD launches new BD Cor molecular diagnostics system
Becton Dickinson (BD) has launched a robotics-based, high-throughput molecular diagnostic system called BD Cor that will be available to labs in the U.S....
BD launches new app for Kiestra lab automation system
Medical technology company Becton Dickinson (BD) announced the U.S. launch of a urine culture application for use with its Kiestra lab automation incubation...

Copyright © 2021

Last Updated np 12/17/2021 3:12:19 PM